+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Metabolites as Signals in Immunity and Inflammation

  • Book

  • January 2024
  • Elsevier Science and Technology
  • ID: 5850273
Metabolites as Signals in Immunity and Inflammation describes the revolution in the definition of the word metabolism, highlighting changes in thinking about the whole field of immunology. These changes occur thanks to breakthrough experiments in basic research, and with the help of new technologies that allow for the testing of immunology hypotheses. In recent years, a substantial number of findings have been made around immunometabolism. What is emerging is a complex interplay between metabolic reprogramming and immunity, which is providing an extra dimension to our understanding of the immune system in health and disease.

Table of Contents

1. Intro chapter: broad intro2. Host-microbe interactions and the role of immunometabolism 3. Immunometabolism and human diseases4. Cell Death and Metabolism5. Oncology and Metabolism6. Cardiovascular System and Metabolism7. Innate Immunity and Metabolism8. Adaptive Immunity and Metabolism9. Autoimmunity and Metabolism10. Epigenetics and Innate Memory Metabolism11. Diabetes, Obesity, and Metabolism12. Metabolism as a Portal to New Therapeutics

Authors

Zbigniew Zaslona Inflammation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Ireland. Dr. Zbigniew Zaslona?currently?serves as?Director of Biology?at OncoArendi. He?obtained?his PhD in 2010 at the University of Giessen and the Marburg Lung Center in Germany, studying the mechanisms that modulate innate immunity in the context of pneumonia.?He then undertook a?postdoctoral fellowship at the University of Michigan in the USA, where he focused on pharmacological studies of GPCR receptors, in particular lipid mediators of inflammation.?From?2015?to October 2020, he?was?a research fellow at Trinity College Dublin (Ireland) in the Department of Biochemistry and Immunology, as well as?a Senior Investigator at the UK?biotechnology company?Sitryx?(which in March 2020 entered into a?$1?bln?collaboration and license?agreementacquired by Lillywith?Eli Lilly), where he was responsible for anti-inflammatory drug development programs. Dr. Zaslona is a recognized international expert in the field of inflammatory processes and lung?diseases and?is?repeatedly invited to lecture at?leading?international scientific conferences. Tristram Ryan Inflammation Research Group, School of Biochemistry and Immunology, Room 4.32, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland. Tristram Ryan is currently undertaking his PhD in the School of Biochemistry and Immunology in Trinity College Dublin, Ireland, in the laboratory of Professor Luke O'Neill. He is studying the role of immunomodulatory drugs in the treatment of inflammation-driven coagulation, termed immunothrombosis, which occurs in conditions such as sepsis and disseminated intravascular coagulation. Tristram is a science enthusiast involved in public engagement and the dissemination of scientific results. He has presented his work at international conferences and as Chairperson of the Trinity College Biochemical Society, organized and hosted a multidisciplinary series of seminars involving scientific leaders from around the world. Luke O. Neill Inflammation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland. Professor Luke O'Neill FRS is the Chair of Biochemistry and Immunology (1960) at Trinity College Dublin, Ireland. He completed his PhD in Pharmacology at the University of London, UK. The O'Neill laboratory has made significant discoveries in our understanding of immune cell signaling pathways, and works on the molecular basis to the inflammatory response, in particular the role of macrophages in regulating human health and disease Professor O'Neill's work has led to the development of novel anti-inflammatory therapies, and he has co-founded the companies Inflazome, which developed anti-NLRP3 inhibitors and was acquired by Roche Ltd in 2020, and Sitryx. Professor O'Neill has received several prestigious international awards, being elected a member of the Royal Irish Academy in 2004, the European Molecular Biology Organisation in 2005, and a Fellow of the Royal Society (FRS) in 2016. He published 4 best-selling scientific books and appearing weekly on Irish radio.